Cargando…

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

The tumor suppressor TP53 is frequently inactivated in a mutation-independent manner in cancers and is reactivated by inhibiting its negative regulators. We here cotarget MDM2 and the nuclear exporter XPO1 to maximize transcriptional activity of p53. MDM2/XPO1 inhibition accumulated nuclear p53 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishida, Yuki, Ishizawa, Jo, Ayoub, Edward, Montoya, Rafael Heinz, Ostermann, Lauren B., Muftuoglu, Muharrem, Ruvolo, Vivian R, Patsilevas, Tallie, Scruggs, Darah A., Khazaei, Shayaun, Mak, Po Yee, Tao, Wenjing, Carter, Bing Z., Boettcher, Steffen, Ebert, Benjamin L., Daver, Naval G., Konopleva, Marina, Seki, Takahiko, Kojima, Kensuke, Andreeff, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2023
Materias:	Biomedicine and Life Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686564/ https://www.ncbi.nlm.nih.gov/pubmed/38019903 http://dx.doi.org/10.1126/sciadv.adh1436

Ejemplares similares

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
por: Senapati, Jayastu, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
por: Chang, Kyung Hee, et al.
Publicado: (2020)

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations
por: Daver, Naval, et al.
Publicado: (2020)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Venetoclax resistance: mechanistic insights and future strategies
por: Ong, Faustine, et al.
Publicado: (2022)

Extended live-cell barcoding approach for multiplexed mass cytometry
por: Muftuoglu, Muharrem, et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience
por: Trabal, Adriana, et al.
Publicado: (2023)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE
por: Sharon, David, et al.
Publicado: (2023)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022)

Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations
por: Dawoud, Ahmed A. Z., et al.
Publicado: (2023)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells
por: Carter, Bing Z., et al.
Publicado: (2015)

Low Expression Of PP2A Regulatory Subunit B55α Is Associated With T308 Phosphorylation Of AKT And Shorter Complete Remission Duration In Acute Myeloid Leukemia Patients
por: Ruvolo, Peter P., et al.
Publicado: (2011)

Development of a large-scale isolation chamber system for the safe and humane care of medium-sized laboratory animals harboring infectious diseases
por: Pan, Xin, et al.
Publicado: (2010)

Distributions of HLA-A and -B alleles and haplotypes in the Yi ethnic minority of Yunnan, China: relationship to other populations
por: Zhu, Bo-feng, et al.
Publicado: (2010)

Sporadic Creutzfeldt–Jakob disease subtype-specific alterations of the brain proteome: Impact on Rab3a recycling
por: Gawinecka, Joanna, et al.
Publicado: (2012)

Surface modifications of influenza proteins upon virus inactivation by β-propiolactone*
por: She, Yi-Min, et al.
Publicado: (2013)

Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues
por: Steiner, Carine, et al.
Publicado: (2014)

MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis
por: Winter, Martin, et al.
Publicado: (2017)

Binodal, wireless epidermal electronic systems with in-sensor analytics for neonatal intensive care
por: Chung, Ha Uk, et al.
Publicado: (2019)

Proteomics insights into DNA damage response and translating this knowledge to clinical strategies
por: von Stechow, Louise, et al.
Publicado: (2016)

Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aggj9i0svvkq3uto8tf1qjlv8p